10170-GMC-14 CRANIOPHARYNGIOMA REFRACTORY TO SURGERY AND RADIOSURGERY SUCCESSFULLY TREATED WITH ENCORAFENIB AND BINIMETINIB: A CASE REPORT
Shota Tanaka, Shunsaku Takayanagi, Hidenori Kage, Katsutoshi Oda, Shozo Yamada, Hirokazu Takami, Nobuhito Saito- Surgery
- Oncology
- Neurology (clinical)
Abstract
Craniopharyngioma is prone to recurrence despite aggressive surgery; repeated surgery and radiotherapy are associated with risks of pituitary insufficiency, visual inacuity and anopsia, and neurocognitive dysfunction, adversely affecting patients' activity of daily life and quality of life. In a recent clinical trial in the US, molecular targeted therapy with vemurafenib and cobimetinib has achieved excellent objective response rate in BRAF-mutant cranopharyngioma. We report a case of BRAF-mutant papillary craniopharyngioma refractory to multiple surgeries and radiosurgery that was successfully treated with encorafenib and binimetinib. Molecular targeted therapy with BRAF inhibitor and MEK inhibitor can be a treatment option for BRAF-mutant craniopharyngioma, even after multiple recurrences with surgeries and radiotherapy.